

# Development of STK25 inhibitor for treatment of nonalcoholic steatohepatitis

Korea Research Institute of Chemical Technology(KRICT)



METABOLIC	Lead
Product Type	Small molecule
Indication	Nonalcoholic steatohepatitis (NASH)
Target	STK25
MoA(Mechanism of Action)	<p>Regulation of liver lipid homeostasis and progression of NAFLD/NASH</p>
Competitiveness	<p>First in Class</p> <p>Novel target-based development of a new therapeutic approach for nonalcoholic fatty liver disease</p>
Development Stage	Lead
Route of Administration	Oral administration